spacer
home > epc > Autumn 2004
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2004
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC
   
Text
PDF
bullet
introduction
In her Editor's Letter, Julia Lloyd-Parks reviews the articles in this issue  
view
bullet
Marketplace & Business
Joseph L Herring, President and Chief Operating Officer at Covance Inc, makes a battlecry for CROs to "collaborate or stagnate", in A Winning Prescription for Drug Development Outsourcing  
view
Recent years have seen the European pharmaceutical and biotechnology industries caught up in a quagmire of re-organisation and increased M&A activity. Nick Stephens, Managing Director at RSA Consulting Ltd and Robert Bates, Managing Director of RSA GmbH, consider the possibilities of Expanding Overseas - What are the Challenges?  
view
In Choosing the Right Translation Services Provider: The Key Facts, Octavia GuzmСn, Head of Scientific Translations at Translator Legal and Financial SL, examines the impact for pharma of nine new official languages in the newly-expanded EU  
view
bullet
Clinical Trials
The 'off label' use of medications in paediatric studies is becoming increasingly widespread. Dr Robert M Nelson, MD, Associate Professor of Anaesthesia and Pediatrics, Department of Anaesthesiology and Critical Care Medicine at The Children's Hospital of Philadelphia, and the University of Pennsylvania, looks at ways of Stimulating Paediatric Drug Research: Comparing the US and EU Approaches - Part I  
view
Lewis Weidman, Director of Vitalograph Ltd, describes the background to COPD and asthma studies, examines areas where data quality can be compromised, and suggests how this can be improved today, in Maximising Data Quality in Respiratory Clinical Trials  
view
In Clinical Trials in Central and Eastern Europe, Giancarlo Carmosino, Clinical Trials and Health Care Technology Development Director of CROM srl and Wanda Malkowska, General Manager of CROM Polska, review the stats suggesting that CEE is a region capable of providing a significant contribution to the development of new drugs for the international market  
view
Professor Georg Dorffner, Chief Executive Officer of The Siesta Group Schlafanalyse GmbH, investigates current trends in sleep medicines research, in Revolutionising Sleep Studies: Making the Most of Multi-Centre Clinical Trials  
view
bullet
Legal & Regulatory
With the accession of 10 countries into the EU, projections of significant parallel trade between old and new member states have been made. In EU Enlargement, Patents and Pharmaceuticals, Christoph T Feddersen, Associate at Cleary, Gottlieb, Steen & Hamilton, Brussels, analyses the Community's new Specific Mechanism provision  
view
In The EU Clinical Trials Directive and the New Europe, Keren Winmill, Director of Pharmaceutical Services at Penn Pharmaceutical Services, ponders whether the addition of 10 member states will improve the climate for research and if implementation of the EU Clinical Trials Directive in Europe will help or hinder that crucial process?  
view
bullet
India Focus
Will India Become the Outsourcing Capital for the Global Pharmaceutical Industry? Dr Nermeen Varawalla, Vice President, Business Development International at PRA International, considers the possibilities  
view
Paul Hunt, Managing Director and CEO of Pharm-Olam International (UK) Ltd, weighs up the pros and cons when Searching Broader Horizons - Opportunities for Clinical Trials in India  
view
bullet
IT Solutions
In Developments in Electronic Data Capture in the Pharmaceutical Sector: Where Data has Full Dominion, Gary Hawksworth, Head of Marketing for Pharmaceuticals at BT, introduces us to the dynamic field of telecare  
view
In today's active climate, who can afford not to employ methods that allow comprehensive surveys of the vast scientific literature freely available for review? James Fickett, Director, Strategic Capabilities, Discovery IS and Informatics, and William Hayes, PhD, Global Cross-Discovery and External Technology Strategic Capability Manager for AstraZeneca, put the spotlight on Text Mining for Drug Discovery  
view
bullet
LIMS & Central Labs
Over the last 10 years, laboratory information management systems have changed beyond recognition. Stefano Marocco, Account Manager and Elian Winstanley, Office Manager at STARLIMS, UK, give us their perspective of the latest Developments and Trends in LIMS - A 'Coming of Age'?  
view
Steve Westcott, Managing Director at Melbourn Scientific, reviews the methods needed to be transferable from different research laboratories in order to face the rigours of external validation and the realities of the production line, and asks How Well Do You Know Your Method?  
bullet
Drug Discovery, Development & Delivery
Graham Buckton, Chief Executive Officer of Pharmaterials Ltd, gives us the low-down on the Physical Characterisation of Powders, explaining why it has become so important and what advances have occurred  
view
In Understanding the Challenges and Opportunities in Nasal Drug Delivery, Dino J Farina, Founder and President of ImageTherm, tackles the key issues of development, formulation, testing and regulation  
view
bullet
Therapeutic Innovation: Cancer Focus
In Conducting Oncology Clinical Studies: Perils, Pitfalls and Practical Tips, patient recruitment difficulties, long timelines, complex study designs and the increasing use of sites around the world are all factors under the microscope of Mark Grose, Vice President, Program Management, at Endpoint Research  
view
Global interest in cancer research continues to concentrate minds from across the pharma industry - the 2004 meeting of the American Society of Clinical Oncology was attended by 25,000 people from 119 countries. Professor Gordon McVie, Oncology Advisor at Inveresk, presents Anticancer Drug Development - A Global View  
view
bullet
LABS & Logistics
In The 'Life' of a Clinical Trial Sample, Helen Springford, Director of Business Development at IMFORM, and Sue Lee, Manager of BioPharm Systems, Research and Development at World Courier, offer us a fascinating insight into the highs and lows experienced by an HIV blood sample from collection to delivery  
view
Stephen Errey, Managing Director at Lucidea Consulting Limited, looks beyond the common perception that logistics is simply a cost to be controlled or a process to be improved to pose the question Logistics - What's In It For You?  
view
 
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

PCI Pharma Services Announces Appointment of Angi Calkins as Chief Human Resources Officer

Philadelphia, PA January 28, 2019. Leading biopharmaceutical services provider PCI Pharma Services (PCI) is pleased to announce the appointment of Angi Calkins as Senior Vice President and Chief Human Resources Officer. Angi joins PCI as the company experiences considerable growth and global expansion, currently with more than 3,500 associates, spanning eight locations comprised of 20 facilities across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement